AID and somatic hypermutation.
In response to an assault by foreign organisms, peripheral B cells can change their antibody affinity and isotype by somatically mutating their genomic DNA. The ability of a cell to modify its DNA is exceptional in light of the potential consequences of genetic alterations to cause human disease and cancer. Thus, as expected, this mechanism of antibody diversity is tightly regulated and coordinated through one protein, activation-induced deaminase (AID). AID produces diversity by converting cytosine to uracil within the immunoglobulin loci. The deoxyuracil residue is mutagenic when paired with deoxyguanosine, since it mimics thymidine during DNA replication. Additionally, B cells can manipulate the DNA repair pathways so that deoxyuracils are not faithfully repaired. Therefore, an intricate balance exists which is regulated at multiple stages to promote mutation of immunoglobulin genes, while retaining integrity of the rest of the genome. Here we discuss and summarize the current understanding of how AID functions to cause somatic hypermutation.
Laboratory of Molecular Gerontology, National Institute on Aging, National Institutes of Health, Baltimore, Maryland, USA.
Robert W
RW
Maul
Patricia J
PJ
Gearhart
D000818:Animals; D000916:Antibody Diversity; D001402:B-Lymphocytes / Q000201:enzymology / Q000276:immunology*; D003564:Cytidine Deaminase / Q000378:metabolism*; D004249:DNA Damage; D004260:DNA Repair; D003641:Deamination; D003845:Deoxycytosine Nucleotides / Q000378:metabolism; D003856:Deoxyuracil Nucleotides / Q000378:metabolism; D005803:Genes, Immunoglobulin; D006801:Humans; D051379:Mice; D027041:Somatic Hypermutation, Immunoglobulin; D000098830:AICDA (Activation-Induced Cytidine Deaminase)
D003845:Deoxycytosine Nucleotides; D003856:Deoxyuracil Nucleotides; D000098830:AICDA (Activation-Induced Cytidine Deaminase); D003564:Cytidine Deaminase